Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 132.39

-0.7%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (932)	5/14/2002 1:30:06 PM
From: keokalani'nui	Read Replies (2) of 1834

Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-.alpha.]-pyrimidin-7-yl} phenyl)acetamide I notice a May 7 patent issue date. On the May 7 CC, company said although original patents (on drugs that led to the commercial 34060 discovery) expire in '03-'04, it had filed composition of matter on commercial candidate and crystalline structure. If I am right that the company would have received a notice of allowance before the company made those comments on May 7 (and I am assuming would have mentioned this), would it be right conclusion that the May 7 patent does not cover the commercial 34060? I found no PubMed reference to commercial 34060 structure, not that I would have know what to do with it had it been revealed. Wilder 90% H20 (laying a little chemistry on y'all)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next